*僅供醫學專業人士閱讀參考

2025國際會議重磅發布！重癥肌無力治療最新突破。

*以下內容僅供在中國大陸執業的

醫療衛生專業人士瀏覽。

參考文獻：

[1]Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36.

[2]Xin H, Harris LA, Aban IB, Cutter G. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample. J Clin Neurol. 2019 Jul;15(3):376-385.

[3]Utsugisawa K Nagane Y Uzawa A Murai H Imai T Suzuki S. Health-related quality of life and treatment strategies in myasthenia gravis. Clin Exp Neuroimmunol. 2020; 11: 209-217.

[4]中國免疫學會神經免疫分會. 中國重癥肌無力診斷和治療指南(2020版)[J]. 中國神經免疫學和神經病學雜志, 2021, 28(1): 1-12. DOI: 10.3969/j.issn.1006-2963.2021.01.001.

[5] Howard JF Jr, Bresch S, Genge A. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023 May; 22(5): 395-406.

[6] Hewamadduma C, et al. Early and Sustained Response Over Time With Zilucoplan in Generalised Myasthenia Gravis: 120-Week Post Hoc Analysis of RAISE-XT. MGFA 2025. Poster 83.

[7] Weiss MD, et al. Effect of zilucoplan on myasthenia gravis-specific outcome subdomain scores in RAISE: A Phase 3 study. AAN 2025. Presentation number: S34:004.

[8] Leite MI, et al. Improvement of Ocular Subdomain Scores With Zilucoplan in Patients With Generalised Myasthenia Gravis in RAISE and RAISE-XT Studies. MGFA 2025. Poster 110.

[9] Jens Schmidt, et al. Concomitant intravenous immunoglobulin or plasma exchange has no effect on complement inhibition with zilucoplan. MGFA 2025. Poster 77.

[10] Channa Hewamadduma, et al. Corticosteroid dose tapering during treatment with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT. MGFA 2025. Poster 84.

[11]Tuan Vu, et al. Non-steroidal immunosuppressant therapy changes during zilucoplan treatment in generalised myasthenia gravis: 120-week follow-up of RAISE-XT. MGFA 2025. Poster 207.

[12]Miriam Freimer, et al. Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in myasthenia gravis: Patient preference and satisfaction from a Phase 3b study. MGFA 2025. Poster 49.

[CN-ZL-2500001 有效期截止：2027年6月] 本內容僅供醫療衛生專業人士閱讀，所含信息不應代替醫療衛生專業人士提供的醫療建議，也不建議醫療衛生專業人士超出說明書范圍使用所涉及的藥物。

*此文僅用于向醫學人士提供科學信息，不代表本平臺觀點